A novel cancer vaccine that stimulates the immune system to target one of the most common cancer-driving mutations has shown ...

While the early-stage results would need to be validated in larger studies, the researchers said the findings offer hope for ...

Led by a team of African researchers, first doses of the novel T cell-inducing GRAdHIVNE1 vaccine candidate have been given.

In the Phase III VAYHIT2 trial, ianalumab combined with eltrombopag significantly prolonged time to treatment failure and ...

A new study reveals that simply seeing a visibly “infectious” figure can set off a chain reaction in the brain’s ...

A novel cancer vaccine that stimulates the immune system to target one of the most common cancer-driving mutations has shown encouraging early results ...

Phase 1 study results published in Nature Medicine looks at a vaccine for patients with pancreatic and colorectal cancer. Dr Magnus Dillon, Clinician Scientist at The Institute of Cancer Research, ...

Adding a MET gene inhibitor enhances the effect of combined chemotherapy and immunotherapy in small cell lung cancer (SCLC), according to a multicenter study led by the Hospital del Mar Research ...

Additionally, a baseline immune response to GP2 was observed before any treatment with GP2 in both HLA-A*02 and non-HLA-A*02 arms. These two immune responses were also observed in the Phase 2b ...

Treatment with the investigative agent GLSI-100 (GP2 plus GM-CSF) demonstrated an increased immune response over time in patients with HER2-positive breast cancer following surgery, according to ...